文献速递神经MR

诊断时颞肌厚度作为胶质母细胞瘤患者肌少症标志物的预后相关性

Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis.
PubMed 文献 · Eur Radiol · 2020-11-17

本研究回顾性纳入51例诊断时MGMT启动子甲基化、IDH1-2野生型胶质母细胞瘤患者,在术前3T MRI上测量颞肌厚度(TMT),分析其与总生存、性别、年龄及ECOG体能状态的关系。中位TMT 8.4 mm组与低TMT组总生存无统计学显著差异(HR 1.34,95%CI 0.68-2.63,p=0.403),TMT与性别相关(p=0.0186),与年龄(p=0.642)及体能状态(p=0.3982)无关。

要点

  • 诊断时TMT中位值8.4 mm,≥8.4 mm组与<8.4 mm组总生存无统计学显著差异。
  • TMT与性别相关(p=0.0186),与年龄(p=0.642)和ECOG体能状态(p=0.3982)无关。
  • 作者认为TMT的用途可能仅局限于脑转移及复发或治疗后的胶质母细胞瘤患者。

核心结论

  • 在诊断时胶质母细胞瘤的同质队列中,TMT与预后、年龄或ECOG体能状态均无关联。

研究设计与样本

  • 回顾性纳入本机构51例MGMT启动子甲基化、IDH1-2野生型胶质母细胞瘤患者,均接受完整手术切除及后续放疗联合替莫唑胺同步和维持治疗,纳入时间为2015年1月1日至2017年4月30日。
  • TMT在术前不超过2天于本院3-T扫描仪采集的增强后3D MPRAGE重格式化图像上双侧测量,末次临床/影像随访日期设为2019年9月3日。
  • 以TMT中位数、第25百分位和第75百分位分组,统计分析总生存(OS)与TMT、性别、年龄及ECOG体能状态的关联。

关键影像表现/征象

  • TMT在增强后3D MPRAGE重格式化图像上双侧测量,中位值为8.4 mm,第25百分位为7 mm,第75百分位为9.85 mm。

诊断标准与关键数值

  • TMT≥8.4 mm(中位值)组对比<8.4 mm组,OS无统计学显著增加(Cox回归模型:HR 1.34,95%CI 0.68-2.63,p=0.403)。
  • TMT≥9.85 mm(第四四分位)组与TMT≤7 mm(第一四分位)组OS无差异。
  • TMT与性别显著相关(p=0.0186),与年龄(p=0.642)和体能状态(p=0.3982)无显著关联。

临床应用与阅片要点

  • 作者认为TMT的用途可能仅局限于脑转移及复发或治疗后的胶质母细胞瘤患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Temporal muscle thickness (TMT) is a surrogate marker of sarcopenia, correlated with survival expectancy in patients suffering from brain metastases and recurrent or treated glioblastoma. We evaluated the prognostic relevance of TMT measured on brain MRIs acquired at diagnosis in patients affected by glioblastoma.

METHODS: We retrospectively enrolled 51 patients in our Institution affected by methylated MGMT promoter, IDH1-2 wild-type glioblastoma, who underwent complete surgical resection and subsequent radiotherapy with concomitant and maintenance temozolomide, from January 1, 2015, to April 30, 2017. The last clinical/radiological follow-up date was set to September 3, 2019. TMT was measured bilaterally on reformatted post-contrast 3D MPRAGE images, acquired on our 3-T scanner no more than 2 days before surgery. The median, 25th, and 75th percentile TMT values were identified and population was subdivided accordingly; afterwards, statistical analyses were performed to verify the association among overall survival (OS) and TMT, sex, age, and ECOG performance status.

RESULTS: In our cohort, the median OS was 20 months (range 3-51). Patients with a TMT ≥ 8.4 mm (median value) did not show a statistically significant increase in OS (Cox regression model: HR 1.34, 95% CI 0.68-2.63, p = 0.403). Similarly, patients with a TMT ≥ 9.85 mm (fourth quartile) did not differ in OS compared to those with TMT ≤ 7 mm (first quartile). The statistical analyses confirmed a significant association among TMT and sex (p = 0.0186), but none for age (p = 0.642) and performance status (p = 0.3982).

CONCLUSIONS: In our homogeneous cohort of patients with glioblastoma at diagnosis, TMT was not associated with prognosis, age, or ECOG performance status.

KEY POINTS: • Temporal muscle thickness (TMT) is a surrogate marker of sarcopenia and has been correlated with survival expectancy in patients suffering from brain metastases and recurrent or treated glioblastoma. • We appraised the correlation among TMT and survival, sex, age at surgery, and performance status, measured on brain MRIs of patients affected by glioblastoma at diagnosis. • TMT did not show any significant correlation with prognosis, age at surgery, or performance status, and its usefulness might be restricted only to patients with brain metastases and recurrent or treated glioblastoma.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Muglia R, Simonelli M, Pessina F, et al. Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis. Eur Radiol. 2020. PMID: 33201284. doi:10.1007/s00330-020-07471-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。